CLTCL1

CLTCL1 encodes CHC22, a human-enriched clathrin heavy-chain isoform that builds triskelion-based vesicle coats biochemically distinct from the ubiquitous CHC17: the CHC22 coat is more pH-stable, is not disassembled by the Hsc70/auxilin uncoating machinery, is differentially recruited by adaptors, and does not support plasma-membrane endocytosis (PMID:29097553). Its central cellular role is the biogenesis of the insulin-responsive GLUT4 storage compartment in human skeletal muscle and adipocytes, a species-restricted function: depletion impairs GLUT4 sequestration, and ectopic expression in mice (which lack the gene) mislocalizes GLUT4 pathway components and produces diabetic features (PMID:19478182). CHC22 acts at the ER-to-Golgi intermediate compartment (ERGIC), where it forms a complex with the tether p115, GLUT4, and sortilin to route GLUT4 into the storage compartment, upstream of a separate retrograde endosome-to-TGN recapture step that requires syntaxin 10 (PMID:20065094, PMID:31863584). Recruitment to ERGIC membranes is bipartite, requiring both the C-terminal trimerization domain binding SNX5/SNX6 (which itself contacts p115) and an isoform-specific N-terminal patch that binds p115 directly; disruption of either interaction blocks GLUT4 targeting (PMID:39160272, PMID:15133132). A common coding variant (V1316) alters CHC22 dynamics and is less effective at controlling GLUT4 traffic, and CLTCL1 is under strong purifying selection in vertebrates retaining it (PMID:31159924). CHC22 is enriched at neuromuscular and myotendinous junctions and is upregulated during myoblast differentiation and muscle regeneration, where it influences fiber-type metabolism (PMID:15133132, PMID:24204966). A balanced translocation truncating CLTCL1 produces features of DiGeorge/velocardiofacial syndrome, implicating haploinsufficiency in that phenotype (PMID:9147638).

1. 1996 Medium

   Establishing that humans possess a second clathrin heavy-chain gene distinct from the canonical CHC17 raised the question of whether a paralog with a specialized function exists.

   Evidence cDNA cloning, sequencing, and Northern analysis of a 1640-aa heavy chain on chromosome 22q11 with 84.7% identity to CHC17 and skeletal-muscle-selective expression

   PMID:8733129 PMID:8844170

   Open questions at the time

   • no functional distinction from CHC17 established at this stage
   • biochemical consequence of the C-terminal alternative splicing untested
   • binding partners unknown
2. 1997 Medium

   Linking CLTCL1 disruption to a developmental syndrome tested whether the gene has a dosage-sensitive role in vivo.

   Evidence Breakpoint cloning of a balanced (21;22) translocation truncating CLTCL1 and Northern detection of the truncated transcript in a patient with DiGeorge/velocardiofacial features

   PMID:9147638

   Open questions at the time

   • single case, causality vs contiguous-gene effects not resolved
   • molecular mechanism connecting truncation to phenotype unknown
3. 2000 Medium

   An ALK fusion to CLTCL1 in anaplastic lymphoma showed that the CHC22 portion confers membrane targeting, indirectly demonstrating its vesicle-associated localization.

   Evidence cDNA cloning of a CLTCL-ALK fusion, immunostaining localizing the fusion to clathrin-coated vesicles, and in vitro kinase autophosphorylation assay

   PMID:10807789

   Open questions at the time

   • informs only the targeting/oligomerization region, not endogenous CHC22 function
   • no normal-cell trafficking readout
4. 2004 Medium

   Identifying SNX5 as a CHC22-specific partner via a domain absent in CHC17 provided the first molecular basis for divergent CHC22 function.

   Evidence Co-immunoprecipitation, domain mapping, fractionation, and immunofluorescence showing a coiled-coil CHC22–SNX5 interaction and junctional/regeneration-linked muscle expression

   PMID:15133132

   Open questions at the time

   • downstream trafficking pathway not yet defined
   • cargo not identified at this stage
5. 2009 High

   Demonstrating that CHC22 is required to build insulin-responsive GLUT4 storage compartments defined its principal physiological cargo and a species-restricted metabolic role.

   Evidence CHC22 knockdown in human cells, CHC22 transgenic mice with GLUT4 mislocalization and diabetic features, and glucose tolerance testing

   PMID:19478182

   Open questions at the time

   • step in the GLUT4 itinerary controlled by CHC22 not yet localized
   • direct molecular interactions with GLUT4 machinery undefined
6. 2010 High

   Placing CHC22 in a retrograde endosome-to-TGN route distinct from CHC17 and retromer identified a specific trafficking step underlying GLUT4 targeting.

   Evidence siRNA knockdown of CHC22 and syntaxin 10, cargo trafficking assays, and fractionation showing independent CHC22/CHC17 function

   PMID:20065094

   Open questions at the time

   • whether retrograde sorting was the primary or a recapture step unresolved at the time
   • coat assembly properties not yet characterized
7. 2017 High

   Reconstituting CHC22 coats biochemically distinguished it from CHC17, explaining how a near-identical heavy chain forms a functionally separate coat.

   Evidence In vitro coat assembly/disassembly, EM of vesicles, endocytosis assays, and adaptor recruitment assays showing pH stability, Hsc70/auxilin resistance, and absence of plasma-membrane endocytosis

   PMID:29097553

   Open questions at the time

   • physiological adaptors and membrane recruitment site not defined
   • structural basis for uncoating resistance not solved
8. 2019 Medium

   A common coding allotype affecting GLUT4 control linked CHC22 sequence variation to metabolic physiology and revealed evolutionary constraint.

   Evidence Population genetics/phylogenetics with functional cellular GLUT4 trafficking assays and live-cell imaging comparing V1316 and M1316 allotypes

   PMID:31159924

   Open questions at the time

   • mechanistic basis for allotype dynamic differences unresolved
   • organismal/clinical metabolic consequences in humans not established
9. 2020 High

   Localizing CHC22 to the ERGIC and identifying a p115–GLUT4–sortilin complex placed CHC22 at an upstream Golgi-bypass step in GSC biogenesis.

   Evidence siRNA knockdown, co-IP, RUSH secretory tracing, immunofluorescence, and a Legionella replication-vacuole assay requiring ERGIC membrane

   PMID:31863584

   Open questions at the time

   • molecular mechanism of CHC22 recruitment to ERGIC not yet defined
   • role of sortilin in the complex not functionally required
10. 2024 High

    Defining a bipartite two-site recruitment mechanism resolved how CHC22 is targeted to ERGIC membranes to direct GLUT4.

    Evidence Co-IP, domain mutagenesis/deletion mapping, SNX5/SNX6 knockdown, and GLUT4 trafficking assays showing both a C-terminal trimerization–SNX5/6 contact and an N-terminal isoform-specific patch binding p115 are independently required

    PMID:39160272

    Open questions at the time

    • structural details of the N-terminal p115 patch not solved
    • regulation of recruitment by insulin signaling not addressed

• How CHC22 coat formation, ERGIC recruitment, and insulin signaling are coordinated to release GLUT4 to the plasma membrane remains unresolved.
• no structure of CHC22 coat or its recruitment interfaces
• mechanism coupling insulin signaling to GSC mobilization undefined
• basis for resistance to Hsc70/auxilin uncoating unexplained